Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient reported outcomes from GRIFFIN Meeting Abstract


Authors: Silbermann, R.; Laubach, J.; Kaufman, J. L.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; Shah, N.; Bumma, N.; Holstein, S. A.; Costello, C.; Jakubowiak, A.; Orlowski, R. Z.; Shain, K. H.; Cowan, A. J.; Gries, K. S.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Richardson, P. G.; Usmani, S.; Voorhees, P. M.
Abstract Title: Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient reported outcomes from GRIFFIN
Meeting Title: 64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 140
Issue: Suppl. 1
Meeting Dates: 2022 Dec 10-13
Meeting Location: New Orleans, LA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2022-11-15
Start Page: 1146
End Page: 1149
Language: English
ACCESSION: WOS:000893223201059
DOI: 10.1182/blood-2022-162313
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Saad Zafar Usmani
    297 Usmani